Seminars in Vascular Surgery (SEMIN VASC SURG)

Publisher: WB Saunders

Journal description

Each issue of Seminars in Vascular Surgery examines the latest thinking on a particular clinical problem and features new diagnostic and operative techniques. The journal allows practitioners to expand their capabilities and to keep pace with the most rapidly evolving areas of surgery.

Current impact factor: 1.58

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 1.583
2012 Impact Factor 1.015
2011 Impact Factor 1.707
2010 Impact Factor 1.5
2009 Impact Factor 1.721
2008 Impact Factor 1.338

Impact factor over time

Impact factor
Year

Additional details

5-year impact 1.28
Cited half-life 6.90
Immediacy index 0.05
Eigenfactor 0.00
Article influence 0.53
Website Seminars in Vascular Surgery website
Other titles Seminars in vascular surgery (Online), Seminars in vascular surgery
ISSN 1558-4518
OCLC 60626665
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

WB Saunders

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • Pre-print allowed on any website or open access repository
    • Voluntary deposit by author of authors post-print allowed on institutions open scholarly website including Institutional Repository, without embargo, where there is not a policy or mandate
    • Deposit due to Funding Body, Institutional and Governmental policy or mandate only allowed where separate agreement between repository and the publisher exists.
    • Permitted deposit due to Funding Body, Institutional and Governmental policy or mandate, may be required to comply with embargo periods of 12 months to 48 months
    • Set statement to accompany deposit
    • Published source must be acknowledged
    • Must link to journal home page or articles' DOI
    • Publisher's version/PDF cannot be used
    • Articles in some journals can be made Open Access on payment of additional charge
    • NIH Authors articles will be submitted to PubMed Central after 12 months
    • Authors who are required to deposit in subject-based repositories may also use Sponsorship Option
    • Publisher last reviewed on 03/07/2015
    • 'WB Saunders' is an imprint of 'Elsevier'
  • Classification
    ​ green

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Surgical correction of vein valve reflux deep venous reflux is valuable adjunct in treatment of selected patient with lower limb venous ulcer. Deep venous obstruction and superficial reflux is must be corrected beforehand. Sustained venous ulcer healing and reduced ambulatory venous hypertension can be achieved in patients with both primary and secondary deep venous insufficiency. When direct valve repair is possible, valvuloplasty is the best option but when this is not feasible, other techniques can be used, including femoral vein transposition into the great saphenous vein, vein valve transplant, neo-valvle construction, or non-autologous artificial venous valve.
    Seminars in Vascular Surgery 06/2015; DOI:10.1053/j.semvascsurg.2015.06.003
  • [Show abstract] [Hide abstract]
    ABSTRACT: The acute-phase protein, C-reactive protein (CRP), was discovered >80 years ago and has been used clinically as a biomarker of inflammation. The measurement of serum CRP levels has proven useful to determine disease progression and the effectiveness of treatments for a number of medical conditions (eg, cancer, infection, and inflammation). During the last 20 years, multiple studies have shown an increased CRP level to be an indicator of risk for coronary artery disease and to be associated with progression of atherosclerotic carotid occlusive disease. In this review, the most recent associations of CRP with cardiovascular disease in both coronary and carotid artery circulations are analyzed. It is imperative that the vascular surgeon and other vascular specialists recognize the relationship between serum CRP levels and atherosclerotic disease to identify at-risk patient populations, screen for occlusive disease severity, and employ this biomarker in patient counseling. Copyright © 2014 Elsevier Inc. All rights reserved.
    Seminars in Vascular Surgery 04/2015; 27(3-4). DOI:10.1053/j.semvascsurg.2015.04.002
  • [Show abstract] [Hide abstract]
    ABSTRACT: Fibrinogen is a large complex glycoprotein that is aids in the formation of blood clots. As an acute phase protein, fibrinogen has clinical application as a biomarker in the management of patient with venous and arterial disease. High levels are associated with inflammation and the risk of cardiovascular disease. During venous and arterial thrombolysis therapy, fibrinogen levels have prognostic significance regarding risk of bleeding. In this review, the application of fibrinogen as a biomarker in care of the vascular surgery patient is detailed.
    Seminars in Vascular Surgery 04/2015; DOI:10.1053/j.semvascsurg.2015.04.003
  • Seminars in Vascular Surgery 04/2015; 27(3-4). DOI:10.1053/j.semvascsurg.2015.04.001
  • [Show abstract] [Hide abstract]
    ABSTRACT: "Optimal" control of serum glucose levels is an important principle in the successful management of diabetes mellitus. Conversely, poorly controlled serum glucose levels are associated with negative sequelae, including accelerated progression of cardiovascular disease, increased mortality, and increased perioperative complications. The importance of glycemic control as a part of appropriate perioperative management is reviewed and target values are recommended. Copyright © 2015. Published by Elsevier Inc.
    Seminars in Vascular Surgery 03/2015; 27(3-4). DOI:10.1053/j.semvascsurg.2015.03.002
  • [Show abstract] [Hide abstract]
    ABSTRACT: Compression of the neurovascular bundle to the upper extremity can occur above or below the clavicle; thoracic outlet syndrome (TOS) is above the clavicle and pectoralis minor syndrome is below. More than 90% of cases involve the brachial plexus, 5% involve venous obstruction, and 1% are associate with arterial obstruction. The clinical presentation, including symptoms, physical examination, pathology, etiology, and treatment differences among neurogenic, venous, and arterial TOS syndromes. This review details the diagnostic testing required to differentiate among the associated conditions and recommends appropriate medical or surgical treatment for each compression syndrome. The long-term outcomes of patients with TOS and pectoralis minor syndrome also vary and depend on duration of symptoms before initiation of physical therapy and surgical intervention. Overall, it can be expected that >80% of patients with these compression syndromes can experience functional improvement of their upper extremity; higher for arterial and venous TOS than for neurogenic compression. Copyright © 2015. Published by Elsevier Inc.
    Seminars in Vascular Surgery 02/2015; 27(2). DOI:10.1053/j.semvascsurg.2015.02.001
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lower limb venous insufficiency resulting from saphenous vein incompetence is a common disorder, increasing with age. For decades, surgical stripping of the great saphenous vein has been the golden standard in varicose vein treatment. The desire to optimize outcome of treatment and reduction of surgical trauma has led to the development of endovenous techniques. Today, several endovenous techniques are available to ablate the saphenous vein segments with abnormal vein valve function. In this review, we discuss the techniques, mechanisms of action, outcome and complications of all endovenous treatment modalities for the treatment of symptomatic lower limb varicose veins.
    Seminars in Vascular Surgery 02/2015; 27(2). DOI:10.1053/j.semvascsurg.2015.02.002
  • [Show abstract] [Hide abstract]
    ABSTRACT: Determining the severity of acute mesenteric ischemia or reperfusion injury can be problematic, as early visceral hypoperfusion is difficult to detect by traditional laboratory testing. Likewise gauging the success of resuscitation and therapeutic intervention is also challenging to determine by laboratory analysis alone. Investigators continue to actively search for plasma biomarkers that will aide clinicians in identifying the early microvascular changes associated with visceral splanchnic malperfusion in an effort to allow for earlier diagnosis and expedient intervention in order to minimize overall intestinal ischemia and reperfusion injury for the potential of improving clinical outcomes. Copyright © 2015 Elsevier Inc. All rights reserved.
    Seminars in Vascular Surgery 01/2015; 27(3-4). DOI:10.1053/j.semvascsurg.2015.01.008
  • Seminars in Vascular Surgery 01/2015; 27(1). DOI:10.1053/j.semvascsurg.2015.01.005
  • [Show abstract] [Hide abstract]
    ABSTRACT: Biochemical markers have the potential to aid the vascular specialist in many ways. On a daily basis, we rely on such markers as d-dimer to help exclude thromboembolic disease and thus limit low-probability ultrasound imaging. Additionally, we use troponin levels to determine myocardial events perioperatively. During the past decade, use of the inflammatory marker C-reactive protein has been recommended by the American Heart Association to further stratify patient cardiovascular risk, and has been studied more extensively in patients with peripheral vascular disease. This review details clinical information published during the past several decades on the application of serum C-reactive protein levels in peripheral arterial disease patients in correlation with disease severity and likelihood of future cardiovascular events, including recent predictive models. Copyright © 2015 Elsevier Inc. All rights reserved.
    Seminars in Vascular Surgery 01/2015; 27(3-4). DOI:10.1053/j.semvascsurg.2015.01.009
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Renal insufficiency is associated with an increased incidence of poor outcomes, including cardiovascular events and death, in the general population. Renal dysfunction appears to have a particularly negative impact in patients undergoing vascular surgery and endovascular therapy. Although the exact mechanism is unknown, increased levels of inflammatory and biochemical modulators associated with adverse cardiovascular outcomes, as well as endothelial dysfunction, appear to play a role in the association between renal insufficiency and adverse outcomes. Outcomes after the surgical and endovascular treatment of abdominal aortic aneurysms, carotid disease, and peripheral arterial disease are all negatively affected by renal insufficiency. Patients with renal dysfunction may warrant intervention for the treatment of critical limb ischemia and symptomatic carotid stenosis, given the comparatively worse outcomes associated with medical management. Open repair of aortic aneurysms and carotid intervention for asymptomatic disease in patients with severe renal dysfunction should be performed with significant caution, as the risks of repair may outweigh the benefits in this population. Further study is needed to better delineate the risks of medical management for these conditions in patients with coexisting severe renal dysfunction. Lastly, current guidelines for the management of vascular diseases, including objective performance goals for critical limb ischemia, are likely not applicable in patients with severe renal insufficiency. Published by Elsevier Inc.
    Seminars in Vascular Surgery 01/2015; 27(3-4). DOI:10.1053/j.semvascsurg.2015.01.006
  • [Show abstract] [Hide abstract]
    ABSTRACT: Biochemical markers of ischemia reperfusion injury have been of interest to vascular surgeons and researchers for many years. Acute limb ischemia is the quintessential clinical scenario where these markers would seem relevant. The use of biomarkers to preoperatively or perioperatively predict which patients will not tolerate limb-salvage efforts or who will have poor functional outcomes after salvage is of immense interest. Creatinine phosphokinase, myoglobin, lactate, lactate dehydrogenase, potassium, bicarbonate, and neutrophil/leukocyte ratios are a few of the studied biomarkers available. Currently, the most well-studied aspect of ischemia reperfusion injury is rhabdomyolysis leading to acute kidney injury. The last 10 years have seen significant progression and improvement in the treatment of rhabdomyolysis, from minor supportive care to use of continuous renal replacement therapy. Identification of specific biomarkers with predictive outcome characteristics in the setting of ischemia reperfusion injury will help guide therapeutic development and potentially mitigate pathophysiologic changes in acute limb ischemia, including rhabdomyolysis. These may further lead to improvements in short- and long-term surgical outcomes and limb salvage, as well as a better understanding of the timing and selection of intervention. Copyright © 2015 Elsevier Inc. All rights reserved.
    Seminars in Vascular Surgery 01/2015; 27(3-4). DOI:10.1053/j.semvascsurg.2015.01.007
  • [Show abstract] [Hide abstract]
    ABSTRACT: Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease and is associated with a risk of limb loss. This vascular condition is currently treated with limb revascularization by surgery or endovascular intervention performed by a variety of specialists. Because both open vascular bypass and the less invasive endovascular therapy can be performed in selected patients with CLI, there exists significant disagreement as to which therapy should be performed first and which is more successful. The paucity of comparative effectiveness data to guide treatment of CLI has prompted a multidisciplinary effort to organize the Best Endovascular Versus Best Surgical Therapy in Patients With CLI (BEST-CLI) trial. The BEST-CLI trial is a pragmatic, multicenter, open-label, randomized trial that compares best endovascular therapy with best open surgical treatment in patients eligible for both treatments. BEST-CLI aims to provide urgently needed clinical guidance for CLI management by using a pragmatic design comparing the effectiveness of established techniques while allowing for the introduction of newer therapies as they become available; a novel primary endpoint that includes limb amputation rates, repeat intervention, and mortality; a multidisciplinary structure that fosters cooperation among interventional cardiologists, interventional radiologists, vascular surgeons, and vascular medicine specialists; and novel techniques to evaluate the cost-effectiveness and quality-of-life outcomes of the two treatment strategies being tested. Copyright © 2015. Published by Elsevier Inc.
    Seminars in Vascular Surgery 01/2015; 27(1). DOI:10.1053/j.semvascsurg.2015.01.003
  • [Show abstract] [Hide abstract]
    ABSTRACT: B-type natriuretic peptide (also known as brain natriuretic peptide or BNP) is a physiologic marker that is often used to assess a patient's global cardiovascular health. BNP is secreted from the ventricular cardiac myocytes in response to stretch that occurs due to increased intravascular volume. PreproBNP is cleaved into BNP and N-terminal proBNP (NT proBNP) to cause diuresis, natriuresis, and vasodilation, and can be measured with a blood laboratory assay test or point-of-care testing. BNP/NT proBNP has been most extensively studied in the diagnosis and management of heart failure, but within the past 5 years, interest has carried over to vascular surgery patients. Studies have demonstrated that elevated levels of BNP/NT-proBNP (typically >100 pg/mL/>300 pg/mL) are associated with major adverse cardiac events at 30 and 180 days. Additional analysis of BNP/NT-proBNP has demonstrated that patients can be classified as very low risk (<19 pg/mL), low risk (<100 pg/mL), intermediate risk (100 to 400 pg/mL), or high risk (>400 pg/mL). BNP/NT-proBNP in the low- and very-low-risk groups suggests patients are unlikely to have a major adverse cardiac event. An elevated BNP/NT-proBNP, excluding those with reasons for abnormal values, suggests the need for additional risk stratification and medical risk factor optimization. A preoperative measure of BNP or NT-proBNP affords an easy and rapid opportunity to individually and objectively quantify perioperative cardiovascular risk. Recent studies have also identified other biomarkers, none superior to BNP or NT-proBNP, but that, when used concomitantly, aid in further stratifying perioperative risk and will likely be the focus of future investigations. Published by Elsevier Inc.
    Seminars in Vascular Surgery 01/2015; 27(3-4). DOI:10.1053/j.semvascsurg.2015.01.004
  • [Show abstract] [Hide abstract]
    ABSTRACT: Concurrent cardiac disease is an important cause of morbidity and mortality in vascular surgical patients. Increasingly, cardiac biomarkers are used to identify cardiac injury in these high-risk patients. This review provides data demonstrating that perioperative troponin elevation correlates with poor short- and long-term outcomes for vascular surgical patients. In addition, the data demonstrate that patients with high circulating troponin levels fair worse than those with lower levels. Early identification of patients with cardiac injury using biomarkers allows timely diagnosis, risk stratification, and aggressive medical therapy for vascular surgical patients. Copyright © 2014 Elsevier Inc. All rights reserved.
    Seminars in Vascular Surgery 01/2015; 27(3-4). DOI:10.1053/j.semvascsurg.2015.01.002
  • [Show abstract] [Hide abstract]
    ABSTRACT: The clinical application of serum biomarker s (d-dimer, C-reactive protein) to predict the natural history of descending thoracic aortic (DTA) dissection remains elusive. In this review, our current understanding of biomarkers in DTA dissection detection , predicting complications, and aiding in patient management is discussed.
    Seminars in Vascular Surgery 01/2015; 27(3-4). DOI:10.1053/j.semvascsurg.2015.01.001
  • [Show abstract] [Hide abstract]
    ABSTRACT: Surgical bypass has traditionally been the gold standard for treating critical limb ischemia caused by isolated infrapopliteal arterial disease (IP CLI). However, as endovascular techniques continue to progress, they are increasingly applied to this patient population, especially to the high-risk surgical cohort or patients with limited surgical options. This enthusiasm to employ endovascular interventions in IP CLI is accompanied by persistent controversies, as demonstrated in the recent literature. Percutaneous transluminal balloon angioplasty has been the predominant endovascular intervention applied to treat IP CLI and recent literature supports its role. The durability of percutaneous transluminal balloon angioplasty is limited, and thus this intervention is recommended for high-risk patients with limited life expectancy. Bare-metal stents for IP CLI currently do not have supportive data to warrant their use as a primary treatment. Newer drug-eluting stents improve patency and prevent restenosis, but they do not significantly improve patient clinical status compared with bare-metal stents alone. Drug-coated balloons are still relatively new tools in this arena and evidence of their safety and clear efficacy are still lacking. The data on atherectomy, in all of its forms, for IP CLI are overall variable, without any clear benefit to justify its increased complication risks and costs over other modalities. Use of retrograde tibial/pedal access for treating IP CLI as a viable alternative to antegrade access and treatment from a totally retrograde approach has recently been described. Level I evidence to aid in clarifying the true efficacy for each of these endovascular modalities is greatly needed. As we await these data, we must remember that, as with any arterial intervention, proper patient selection is extremely important and the intervention, whether endovascular or open surgical repair, should be tailored to the individual patient's anatomy and disease characteristics. Copyright © 2014 Elsevier Inc. All rights reserved.
    Seminars in Vascular Surgery 12/2014; 27(1). DOI:10.1053/j.semvascsurg.2014.12.003
  • [Show abstract] [Hide abstract]
    ABSTRACT: The angiosome hypothesis states that the surface of the lower extremity is supplied by arteries consistently corresponding to regions of the foot. There is limited and conflicting evidence suggesting that angiosome-directed interventions improve wound healing and limb salvage. As peripheral arterial disease progresses, collaterals may develop that confound a predetermined angiosome map. In selecting a revascularization target vessel for patients with tissue loss, good surgical judgment should prevail, including consideration of the angiosome concept to optimize tissue healing. Copyright © 2014. Published by Elsevier Inc.
    Seminars in Vascular Surgery 11/2014; 27(1). DOI:10.1053/j.semvascsurg.2014.11.003
  • [Show abstract] [Hide abstract]
    ABSTRACT: The application of gene- and cell-based therapies to promote angiogenesis is a novel concept to treat lower-limb critical limb ischemia (CLI) and may provide an unmet need for patients with no options for revascularization. Proof of concept was demonstrated in animal models resulting in clinical trials that have confirmed the feasibility and short-term efficacy of intramuscular injection of angiogenetic tissue growth factors or bone marrow stem cells. The safety of these biologic therapies has been demonstrated in randomized clinical trials with no "off-target" angiogenesis, growth of occult tumors, or progression of diabetic retinopathy. Current phase III randomized clinical trials using a DNA plasmid with the hepatocyte growth factor gene or bone marrow aspirate concentrate of mesenchymal cells are designed to address several crucial issues, including proper patient selection criteria, relevant clinical endpoints, and long-term efficacy. Because effectiveness of these novel therapies remains to be established, ongoing and future randomized clinical trials should be placebo-controlled, investigator-blinded, and have amputation-free survival as the primary endpoint. Further development of efficient gene transfer techniques and keeping transplanted stem cells healthy have the potential to make biologic therapies more robust in promoting angiogenesis, tissue regeneration, and resolution of CLI symptoms. If sustained efficacy can be demonstrated, new therapeutic strategies for patients with CLI will be available for clinicians, ie, limb revascularization using angiogenic gene or stem cell therapy alone, or in conjunction with endovascular intervention. Copyright © 2014 Elsevier Inc. All rights reserved.
    Seminars in Vascular Surgery 10/2014; 27(1). DOI:10.1053/j.semvascsurg.2014.10.001